EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

Jul 7, 2020 | Blog, News, Press Releases | 0 comments

EVQLV

NEW YORK, NY and SOUTH SAN FRANCISCO, Calif – July 7, 2020 — EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

Under the terms of the co-development agreement, EVQLV will computationally generate and rapidly screen a large set of diverse antibody candidates to a specific target using its proprietary algorithms. The sequences of potential antibodies will then be submitted to Twist Bioscience for molecular synthesis, antibody expression, and functional analysis using its synthetic DNA platform. 

“We were impressed with the creative and thoughtful approach the team at EVQLV has taken to antibody design using artificial intelligence and deep learning,” commented Aaron Sato, Ph.D., Chief Science Officer of Twist Biopharma, a division of Twist Bioscience. “This collaboration allows us to continue to expand the benefit of our synthetic DNA platform by manufacturing specific antibody therapies designed by computational modeling that potentially could have a better chance of success.” 

Using an amino acid sequence as an input, EVQLV applies its proprietary AI-generated model of evolution. The model uses billions of public and proprietary data points, including sequence, structure, and biophysical properties to learn the patterns of human antibody formation against the target. This generates variants on a scale of 1-2 million per antibody chain in a process that takes less than 6 hours, a process that can take months in the laboratory. The sequences of the antibodies with the most chance of success will be sent to Twist Bioscience for manufacture and validation.

“Our AI is designed to allow us to quickly and intelligently design biologics, in this case therapeutic antibodies, with a lower risk of failure,” said Andrew Satz, CEO and co-founder of EVQLV. “Twist can then deploy its incredible technology to rapidly synthesize and validate those antibodies. This collaboration combines synthetic biology with computational biology and pushes the boundaries of sci-tech. By working with Twist, we can advance the fusion of science and tech and accelerate the design and development of healing.”

About EVQLV

EVQLV develops artificial intelligence, engineered with life science data and biological knowledge, to accelerate the speed at which biologic therapies reach patients. Comprised of experts in machine learning, molecular biology, computational biology, pharmacology, software engineering, antibody design, cloud computing, and preclinical/clinical development, EVQLV is on a mission to transform how healing reaches those in need. For further information, visit www.evqlv.com.

Follow us on Twitter | Facebook | LinkedIn | YouTube

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation Twist’s ability to discover new antibody therapeutics together with EVQLV, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q dated May 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Twist Bioscience Contacts:
Media Contact: Angela Bitting
925- 202-6211
[email protected]

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (Issuewire.com)  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...

Pin It on Pinterest